The quasi species nature of a human immunodeficiency virus type 1 (HIV-1) infection coupled with the virus's ability to rapidly mutate away from selective drug pressure has led to the use of multiple drugs in combination as the accepted paradigm for treating systemic HIV-1 infections. Therefore it is quite likely that to obtain a safe and effective anti-HIV-1 microbicide a similar approach will be employed. The long-term objectives this """"""""Integrated preclinical program for topical microbicides"""""""", is to provide data that will help justify the clinical development and commercialization of polyethylene-hexamethylene biguanide (PEHMB or PEHMB-derived product) alone or as part of a combination regimen. PEHMB is a potent inhibitor of HIV-1 with minimal toxicity yielding a therapeutic index >1400. Mechanism of action studies has provided evidence that PEHMB's antiviral activity is due to interference with virus binding to the cellular receptors CXCR4 and CCR5. In addition, large-scale production of PEHMB is estimated to be extremely inexpensive (dollars/kg), and we have found PEHMB to be extremely compatible with and stable in normal vaginal gel viscosity building agents. All of these attributes are promising enough to warrant further preclinical evaluation of this compound. In preliminary studies we have also combined PEHMB with members of other classes of putative anti-HIV-1 microbicides including a sulfated dendrimer developed by Dr. Shengrund at Penn State College of Medicine. We propose in this Program to identify the best PEHMB-based combination of drug candidates to maximize the suppressive effect on HIV-1 transmission. This program will involve three research projects integrated into one program. Project I will continue to refine antiviral efficacy and cellular toxicity parameters of the PEHMB scaffold based on computational approaches coupled to iterative rounds of feedback from our biochemical and biological assay systems. In addition, in Project I we will purify PEHMB, work to understand its structure, perform pharmacokinetic and murine toxicity studies as well as begin pre-formulation and formulation work for use in in vivo experimentation and manufacturing schemes. Project II will have the important task of assessing the relative toxicity of PEHMB utilizing both in vitro and in vivo model systems while at the same time provide the intellectual lead in our understanding of the molecular mechanism(s) b y which the PBG class of compounds inhibit virus replication and elicit cellular toxicity. Project II will also examine the impact of microbicides on the intra-vaginal and cervical immune response utilizing well-defined animal models. In Project Ill, we will use state of the art in vitro and in vivo model systems to profile the antiviral efficacy of our lead compound or combination. Project III will examine preformulation parameters, and test the efficacy of the formulated products in vitro including systematic studies to develop combination microbicides based on PEHMB and then test these formulated combinations using xenograph model systems developed by the investigators. All of the efforts outlined in the three projects are focused on providing information needed to move PEHMB and its viable combinations from a pre-clinical to a clinical stage in the drug discovery/development pipeline, with the goal of offering a new class of compounds with specific mode of action distinct from other compounds currently in clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
3U19AI076965-04S1
Application #
7492524
Study Section
Special Emphasis Panel (ZRG1-AARR-A (51))
Program Officer
Turpin, Jim A
Project Start
2007-09-30
Project End
2009-08-31
Budget Start
2007-09-30
Budget End
2009-08-31
Support Year
4
Fiscal Year
2007
Total Cost
$148,098
Indirect Cost
Name
Novaflux Biosciences, Inc.
Department
Type
DUNS #
146264242
City
Princeton
State
NJ
Country
United States
Zip Code
08540
Weaver Jr, Alan J; Shepard, Joyce B; Wilkinson, Royce A et al. (2014) Antibacterial activity of THAM Trisphenylguanide against methicillin-resistant Staphylococcus aureus. PLoS One 9:e97742
Wilkinson, Royce A; Pincus, Seth H; Song, Kejing et al. (2013) Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection. Bioorg Med Chem Lett 23:2197-201
Lozenski, Karissa; Ownbey, Robert; Wigdahl, Brian et al. (2012) Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety. BMC Pharmacol Toxicol 13:9
Pirrone, Vanessa; Passic, Shendra; Wigdahl, Brian et al. (2012) Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virol J 9:33
Lozenski, Karissa; Kish-Catalone, Tina; Pirrone, Vanessa et al. (2011) Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model. J Biomed Biotechnol 2011:941061
Pirrone, Vanessa; Thakkar, Nina; Jacobson, Jeffrey M et al. (2011) Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother 55:1831-42
Wilkinson, Royce A; Pincus, Seth H; Shepard, Joyce B et al. (2011) Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4. Antimicrob Agents Chemother 55:255-63
Passic, Shendra R; Ferguson, Mary Lee; Catalone, Bradley J et al. (2010) Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed Pharmacother 64:723-32
Pirrone, Vanessa; Passic, Shendra; Wigdahl, Brian et al. (2010) A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection. J Biomed Biotechnol 2010:548749
Thakkar, Nina; Pirrone, Vanessa; Passic, Shendra et al. (2010) Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother 54:1965-72

Showing the most recent 10 out of 11 publications